Serum bile acids in cystic fibrosis patients - glycodeoxycholic acid as a potential marker of liver disease
| Autor: | Jarosław Walkowiak, Jan Krzysztof Nowak, Artur Szwengiel, Raisa Aringazina, Patrycja Krzyżanowska-Jankowska, Nataliya Kashirskaya, Sylwia Drzymała, Sławomira Drzymała-Czyż, Agata Nowicka, Krzysztof Dziedzic |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Liver Cirrhosis Male medicine.medical_specialty Cirrhosis Adolescent Cystic Fibrosis medicine.drug_class Cystic fibrosis Gastroenterology Bile Acids and Salts chemistry.chemical_compound Liver disease Young Adult Internal medicine medicine Humans Hepatology Bile acid business.industry Liver Diseases Deoxycholic acid Cholic acid medicine.disease Glycodeoxycholic acid chemistry Case-Control Studies Glycodeoxycholic Acid Biomarker (medicine) Female business Biomarkers |
| Zdroj: | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 54(1) |
| ISSN: | 1878-3562 |
| Popis: | BACKGROUND Cystic fibrosis (CF) and CF-related liver disease can lead to disturbances in bile acid metabolism. AIM This study determined serum bile acid concentrations in CF to define their usefulness in liver disease assessment. METHODS Primary, secondary and conjugated bile acid levels were measured in three CF groups (25 patients each) exhibiting: liver cirrhosis, other liver disease, no liver disease, and in 25 healthy subjects (HS). RESULTS Bile acid levels were higher in CF patients than in HS, except for glycodeoxycholic acid (GDCA). However, bile acid concentrations did not differ between patients with cirrhosis and other liver involvement. GDCA and deoxycholic acid (DCA) differentiated CF patients with non-cirrhotic liver disease from those without liver disease (GDCA-AUC: 0.924, 95%CI 0.822-1.000, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect